Patent intelligence · CA
CA 2754902
COMPOSES D'ACIDE GRAS ESSENTIEL
COMPOSES D'ACIDE GRAS ESSENTIEL
Patent details — CA 2754902
- Jurisdiction
- CA
- Status
- granted
- Grant date
- Sep 16, 2010
- Expiration
- Sep 11, 2030
- Applicant
- AMARIN NEUROSCIENCE LTD [GB]
- CPC classes
- A61K 31/ 21 A I, A61K 31/ 165 A I, A61K 31/ 192 A I, A61P/2100
Quick answer
CA 2754902 (COMPOSES D'ACIDE GRAS ESSENTIEL) is held by AMARIN NEUROSCIENCE LTD [GB]. Status: granted. Granted Sep 16, 2010. Expires Sep 11, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AMARIN NEUROSCIENCE LTD [GB]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 21 A I, A61K 31/ 165 A I, A61K 31/ 192 A I, A61P/2100, A61P/2514, A61P/2516
More from AMARIN NEUROSCIENCE LTD [GB]
Related pharmaceutical patents in our USPTO index.
-
IL 159038
USE OF COENZYME Q AND EICOSAPENTAENOIC ACID (EPA) FOR THE PREPARATION OF MEDICAMENTS
granted -
DK 1007053
Behandling af smerte
granted -
CA 2591889
TRAITEMENT DE LA DEPRESSION MELANCOLIQUE SEVERE A L'AIDE D'EPA
granted -
SI 1148873
HIGHLY PURIFIED ETHYL EPA AND OTHER EPA DERIVATIVES FOR NEUROLOGICAL DISORDERS
expired -
IS 7744
Eikósapentanó sýra (EPA) til notkunar við meðhöndlun á lystarstoli (AN) og matgræðgi
expired -
CA 2506727
TRAITEMENT DE LA MALADIE DE HUNTINGTON AU MOYEN D'ACIDE EICOSAPENTAENOIQUE
expired -
EP 1392276
VERSTÄRKTE WIRKUNG MEHRFACH UNGESÄTTIGTER FETTSÄUREN
expired
Frequently asked questions
What is US patent 2754902?
CA 2754902 (COMPOSES D'ACIDE GRAS ESSENTIEL) is held by AMARIN NEUROSCIENCE LTD [GB]. Status: granted. Granted Sep 16, 2010. Expires Sep 11, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 2754902?
AMARIN NEUROSCIENCE LTD [GB] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 11 pharmaceutical patents for this assignee.
When does CA 2754902 expire?
Our index shows an expiration date of Sep 11, 2030 (4 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.